Polymorphism within the tumor necrosis factor α (TNF) promoter region in patients with ankylosing spondylitis

被引:43
|
作者
Kaijzel, EL [1 ]
Brinkman, BMN [1 ]
van Krugten, MV [1 ]
Smith, L [1 ]
Huizinga, TWJ [1 ]
Verjans, GMGM [1 ]
Breedveld, FC [1 ]
Verweij, CL [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands
关键词
tumor necrosis factor alpha; gene polymorphism; ankylosing spondylitis; HLA-B27;
D O I
10.1016/S0198-8859(98)00099-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In addition to HLA-B27, other genetic factors are thought to be involved in the pathogenesis of ankylosing spondylitis (AS). Because of the location of the TNF gene in the vicinity of the HLA-B locus, and the prominent role in inflammation of its produce, we investigated the association between BS and two G to A transition polymorphisms located at position -238 and -376 in the promoter region of the TNF gene. The distribution of the TNF alleles was determined in 86 HLA-B27+ AS patients and 163 healthy controls. From the 86 AS patients, 33 suffered from acute anterior uveitis (AAU). No significant difference for the TNF-376 polymorphism in AS and healthy controls was observed. The frequency of the TNF-238A allele in HLA-B27(+) AS patients was significantly decreased compared to random controls (p = 0.021). However, the frequency of the TNF-238A allele in HLA-B27(+) AS patients was not significantly different from chat observed in HLA-B27(+) healthy individuals (p = 0.6). Assessment of association showed that the TNF-238G allele is in linkage disequilibrium with the HLA-B27 allele (Delta = 0.051; P = 0.008). Therefore, we conclude that the association between TNF-238G and AS is secondary to the HLA-B27 gene and that TNF-238 and TNF-376 alleles are nor likely to be involved in the susceptibility to AS. Human Immunology 60, 140-144 (1999). (C) American Society for Histocompatibility and Immunogenetics, 1999. Published by Elsevier Science Inc.
引用
收藏
页码:140 / 144
页数:5
相关论文
共 50 条
  • [21] Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis
    Davis, JC
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (04) : 668 - 677
  • [22] Therapeutic Controversies Tumor Necrosis Factor α Inhibitors in Ankylosing Spondylitis
    Song, I. H.
    Maksymowych, W. P.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2012, 38 (03) : 613 - +
  • [23] −383 A/C tumor necrosis factor receptor 1 polymorphism and ankylosing spondylitis in Mexicans: a preliminary study
    Esther Guadalupe Corona-Sanchez
    José Francisco Muñoz-Valle
    Laura Gonzalez-Lopez
    Julia Dolores Sanchez-Hernandez
    Monica Vazquez-Del Mercado
    Heriberto Ontiveros-Mercado
    Miguel Huerta
    Xochitl Trujillo
    Alberto Daniel Rocha-Muñoz
    Alfredo Celis
    Ricardo Ortega-Flores
    Jorge Ivan Gamez-Nava
    Rheumatology International, 2012, 32 : 2565 - 2568
  • [24] -383 A/C tumor necrosis factor receptor 1 polymorphism and ankylosing spondylitis in Mexicans: a preliminary study
    Guadalupe Corona-Sanchez, Esther
    Francisco Munoz-Valle, Jose
    Gonzalez-Lopez, Laura
    Dolores Sanchez-Hernandez, Julia
    Vazquez-Del Mercado, Monica
    Ontiveros-Mercado, Heriberto
    Huerta, Miguel
    Trujillo, Xochitl
    Daniel Rocha-Munoz, Alberto
    Celis, Alfredo
    Ortega-Flores, Ricardo
    Ivan Gamez-Nava, Jorge
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (08) : 2565 - 2568
  • [25] Effect of tumor necrosis factor inhibitors on spinal radiographic progression in patients with ankylosing spondylitis
    Jeong, Hyemin
    Eun, Yeong Hee
    Kim, In Young
    Park, Eun-Jung
    Kim, Hyungjin
    Lee, Jaejoon
    Jeon, Chan Hong
    Koh, Eun-Mi
    Cha, Hoon-Suk
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (05) : 1098 - 1105
  • [26] Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis
    Manolova, Irena
    Ivanova, Mariana
    Stoilov, Rumen
    Rashkov, Rasho
    Stanilova, Spaska
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2014, 28 (06) : 1108 - 1114
  • [27] The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
    Wronski, Jakub
    Fiedor, Piotr
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 445 - 462
  • [28] Interleukin 6 gene promoter polymorphism is not associated with ankylosing spondylitis
    Collado-Escobar, MD
    Nieto, A
    Matarán, L
    Raya, E
    Martín, J
    JOURNAL OF RHEUMATOLOGY, 2000, 27 (06) : 1461 - 1463
  • [29] Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis
    Huang, Jin-Xian
    Lee, Yung-Heng
    Wei, James Cheng-Chung
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 112
  • [30] Efficacy of Antitumor Necrosis Factor(α) Agents on Patients With Ankylosing Spondylitis
    Ren, Lei
    Li, Jianbo
    Luo, Rong
    Tang, Renkuan
    Zhu, Sumin
    Wan, Lihua
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2013, 346 (06): : 455 - 461